Skip to main content

Table 2 Multivariate Cox regression analysis of overall survival in each dataset

From: An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy

 Multivariate analysis
HR95% CIp value
Training cohort
 GSE31312 (n = 449)
  Age1.031.01–1.041.38 × 10−5
  Extra nodal sites number1.201.03–1.412.37 × 10−2
  Stage1.311.12–1.526.26 × 10−5
  ECOGa1.411.21–1.647.33 × 10−6
  Resistance probability of doxorubicin2.701.24–5.861.23 × 10−2
  Resistance probability of vincristine1.280.61–2.700.51
Validating cohort
 GSE10846 (n = 342)
  Age1.021.01–1.041.45 × 10−4
  Extra nodal sites number0.990.80–1.220.95
  Stage1.411.19–1.675.40 × 10−5
  ECOGa1.591.32–1.916.43 × 10−7
  Resistance probability of doxorubicin3.241.41–7.455.61 × 10−3
  Resistance probability of vincristine1.400.61–3.230.43
  1. HR hazard ratio, 95% CI 95% confidence interval
  2. aThe Eastern Cooperative Oncology Group (ECOG) performance score ranges from 0 to 3, with a higher score indicating greater impairment